Fig. 1 · Structure

Documents & Downloads

BIIE 0246

Cat. No. A12158 CAS 246146-55-4

NPY Y2 receptor antagonist

BIIE 0246 is a potent, selective and competitive non-peptide antagonist for the neuropeptide Y Y2 receptor (IC50 = 15 nM).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
NPY Y2 receptor IC50 15±3 nM

BIIE 0246 Research Summary

This section summarizes 4 in vivo studies of BIIE 0246 from 3 published references. In vivo models include male BALB/c mice.

BIIE 0246 In Vivo Studies

Daily intraperitoneal BIIE 0246 increased insulin and HOMA-IR in chow-fed wild-type mice and homozygous transgenic male OE-NPYDβH animals, but not in DIO. In male Yorkshire pigs, intravenous BIIE 0246 significantly reduced the effects of bilateral stellate ganglia stimulation on left ventricular systolic pressure in the pre-BIIE versus post-BIIE comparison. In male BALB/c mice, albuminuria was significantly reduced in the ADR+BIIE0246 group compared with the ADR+Vehicle group at 14 d. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Insulin responses in wild-type mice

Animal study · WT mice on a C57Bl/6N background; WT (n = 11–13) [1]

Wild-type mice received daily intraperitoneal BIIE 0246 at 1.3 mg/kg. Treatment increased insulin and HOMA-IR in chow-fed groups but not in DIO.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Insulin (μg l-1)serum insulin WT, chow diet-fed cohort after 4.5 weeks of treatment: 0.44 ± 0.04 μg l-1[1]

Conditions shared by the study groups

Route
intraperitoneal (i.p.) injections
Treatment course
daily intraperitoneal (i.p.) injections; a chow diet-fed cohort after 4.5 weeks of treatment and a Western diet-fed cohort after 2 weeks of treatment
Vehicle
vehicle (DMSO, Tween® 80) (Fisher Scientific, Fair Lawn, NJ, United States and 0.9% NaCl, 1:1:18, respectively)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
BIIE 0246 1.3 mg/kgVehicleBIIE0246 increased insulin and HOMA-IR in chow fed groups but not in DIO; WT, chow diet-fed cohort after 4.5 weeks of treatment: Insulin (μg l-1), 0.44 ± 0.04[1]
BIIE 0246 1.3 mg/kg
Model: WT mice on a C57Bl/6N background; WT (n = 11–13)
Methods and source locations

Compound reported in the paper: BIIE 0246

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals (S1); Materials and Methods > Experimental Procedures (S14); Results > Blood Glucose and Lipids (S61); Table 1 legend (S114, S115); Table 1 (T1.h2, T1.h3, T1.r2)

Insulin (μg l-1): Insulin (μg l-1); comparator: Vehicle — Results > Blood Glucose and Lipids (S61); Table 1 legend (S114); Table 1 (T1.h2, T1.h3, T1.r2)

BIIE 0246 1.3 mg/kg · Materials and Methods > Experimental Procedures (S14); Results > Blood Glucose and Lipids (S61); Table 1 legend (S114); Table 1 (T1.h2, T1.h3, T1.r2)

Ventricular pressure response during sympathetic stimulation in pigs

Animal study · male Yorkshire pigs; n = 8 [2]

Male Yorkshire pigs received an intravenous BIIE bolus followed by infusion. In the pre-BIIE versus post-BIIE comparison, the effects of bilateral stellate ganglia stimulation on left ventricular systolic pressure were significantly reduced post-BIIE.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
left ventricular systolic pressure (LVSP)LVSP Δ65.6 ± 10.2 mmHg pre-BIIE vs. Δ46.9 ± 8.6 mmHg post-BIIE[2]

Conditions shared by the study groups

Route
infused intravenously
Treatment course
A 20-min acclimation period with continuous infusion of BIIE; during the first 45 s of sympathetic stimulation prior to VNS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
BIIE 0246 32 nmol/kg bolus followed by a 2 nmol/kg/min infusionBSS pre- vs. post-BIIEThe effects of BSS on LVSP were significantly reduced post-BIIE (Δ65.6 ± 10.2 mmHg pre-BIIE vs. Δ46.9 ± 8.6 mmHg post-BIIE; P = 0.05, Figure 3).[2]
BIIE 0246 32 nmol/kg bolus followed by a 2 nmol/kg/min infusion
Model: male Yorkshire pigs; n = 8
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: BIIE 0246

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Porcine studies > Experimental protocol (S25); Methods > Porcine studies > Stellate ganglia stimulations (S49); Methods > Porcine studies > Infusion of Y2R blocker (S59, S60); Results > Effects of muscarinic blockade on NPY in vivo (S92); Results > Haemodynamic and electrophysiological effects of BSS pre- vs. post-BIIE administration (S98, S100); Figure 3 legend (S140, S141); Figure 4 legend (S150)

left ventricular systolic pressure (LVSP): left ventricular systolic pressure (LVSP); comparator: BSS pre- vs. post-BIIE — Results > Effects of muscarinic blockade on NPY in vivo (S92); Results > Haemodynamic and electrophysiological effects of BSS pre- vs. post-BIIE administration (S100)

BIIE 0246 32 nmol/kg bolus followed by a 2 nmol/kg/min infusion · Methods > Porcine studies > Infusion of Y2R blocker (S59, S60); Results > Haemodynamic and electrophysiological effects of BSS pre- vs. post-BIIE administration (S98, S100)

Albuminuria response in Adriamycin-treated mice

Animal study · male BALB/c mice [3]

Male BALB/c mice receiving Adriamycin were treated with BIIE 0246 by daily intraperitoneal injection or subcutaneous osmotic minipump. Albuminuria was significantly reduced in the ADR+BIIE0246 group compared with the ADR+Vehicle group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
uACRsReported result A significant reduction in albuminuria is observed in the ADR+BIIE0246 group, compared with ADR+Vehicle group at 14 d.[3]

Conditions shared by the study groups

Route
daily intraperitoneal (i.p.) injection or subcutaneous osmotic minipump
Treatment course
for 14 d
Vehicle
dimethylsulfoxide (BIIE0246 vehicle)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
BIIE 0246 10 μg/dayADR+Vehicle groupA significant reduction in albuminuria is observed in the ADR+BIIE0246 group, compared with ADR+Vehicle group at 14 d.[3]
BIIE 0246 10 μg/day
Model: male BALB/c mice
Methods and source locations

Compound reported in the paper: BIIE 0246

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Inhibiting NPY2R In Vivo Reduces Albuminuria in Adriamycin Nephropathy. (S41); Materials and Methods > Animal Studies. (S77); Fig. 8. legend (S140, S141, S143, S144)

uACRs: uACRs; comparator: ADR+Vehicle group — Fig. 8. legend (S143, S144)

BIIE 0246 10 μg/day · Results > Inhibiting NPY2R In Vivo Reduces Albuminuria in Adriamycin Nephropathy. (S41); Materials and Methods > Animal Studies. (S77); Fig. 8. legend (S144)

Insulin responses in transgenic animals

Animal study · Homozygous transgenic male OE-NPYDβH; C57Bl/6N background; NPY (n = 11–12) [1]

Homozygous transgenic male OE-NPYDβH animals received daily intraperitoneal BIIE 0246 at 1.3 mg/kg. Treatment increased insulin and HOMA-IR in chow-fed groups but not in DIO.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Insulin (μg l-1)serum insulin NPY, chow diet-fed cohort after 4.5 weeks of treatment: 0.51 ± 0.06 μg l-1[1]

Conditions shared by the study groups

Route
intraperitoneal (i.p.) injections
Treatment course
daily intraperitoneal (i.p.) injections; a chow diet-fed cohort after 4.5 weeks of treatment and a Western diet-fed cohort after 2 weeks of treatment
Vehicle
vehicle (DMSO, Tween® 80) (Fisher Scientific, Fair Lawn, NJ, United States and 0.9% NaCl, 1:1:18, respectively)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
BIIE 0246 1.3 mg/kgVehicleBIIE0246 increased insulin and HOMA-IR in chow fed groups but not in DIO; NPY, chow diet-fed cohort after 4.5 weeks of treatment: Insulin (μg l-1), 0.51 ± 0.06[1]
BIIE 0246 1.3 mg/kg
Model: Homozygous transgenic male OE-NPYDβH; C57Bl/6N background; NPY (n = 11–12)
Methods and source locations

Compound reported in the paper: BIIE 0246

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals (S1); Materials and Methods > Experimental Procedures (S14); Results > Blood Glucose and Lipids (S61); Table 1 legend (S114, S115); Table 1 (T1.h2, T1.h3, T1.r2)

Insulin (μg l-1): Insulin (μg l-1); comparator: Vehicle — Results > Blood Glucose and Lipids (S61); Table 1 legend (S114); Table 1 (T1.h2, T1.h3, T1.r2)

BIIE 0246 1.3 mg/kg · Materials and Methods > Experimental Procedures (S14); Results > Blood Glucose and Lipids (S61); Table 1 legend (S114); Table 1 (T1.h2, T1.h3, T1.r2)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 246146-55-4
Applications

NPY Y2 receptor antagonist

Formula C49H57N11O6
Molecular Weight 896.06
SMILES
C1CCC(C1)(CC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCN2C(=O)N(N(C2=O)C3=CC=CC=C3)C4=CC=CC=C4)CC(=O)N5CCN(CC5)C6C7=CC=CC=C7C(=O)NC8=CC=CC=C68

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

BIIE 0246 Research References

  1. [1] Ailanen L, Vähätalo LH, Salomäki-Myftari H, et al. Peripherally Administered Y2-Receptor Antagonist BIIE0246 Prevents Diet-Induced Obesity in Mice With Excess Neuropeptide Y, but Enhances Obesity in Control Mice. Front Pharmacol (2018). PMID: 29674968 DOI: 10.3389/fphar.2018.00319 Source material
  2. [2] Jani NR, van Weperen VYH, Ayagama T, et al. Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn reduce NPY levels via muscarinic receptor activation. Cardiovasc Res (2025). PMID: 41052902 DOI: 10.1093/cvr/cvaf180 Source material
  3. [3] Lay AC, Barrington AF, Hurcombe JA, et al. A role for NPY-NPY2R signaling in albuminuric kidney disease. Proc Natl Acad Sci U S A (2020). PMID: 32561647 DOI: 10.1073/pnas.2004651117 Source material

Added to your cart

View Cart Checkout
Loading...